Atosiban

Summary

Atosiban is a synthetic peptide that blocks oxytocin receptors and is approved as a prescription drug for acute tocolysis—temporarily halting uterine contractions in women with threatened preterm birth. It is administered intravenously in a hospital setting. Research also explores its use for maintenance tocolysis and as an adjunct around embryo transfer in assisted reproduction.

Mechanism of Action

Atosiban is an analogue of oxytocin and vasopressin that competitively binds to the oxytocin receptor on uterine smooth‑muscle cells, preventing oxytocin‑induced calcium influx and contraction. By inhibiting this pathway, it reduces the frequency and intensity of uterine contractions without significant activation of vasopressin receptors, allowing a temporary pause in labour progression.

What the Research Shows

Randomised controlled trials and systematic reviews provide a mixed picture. The large APOSTEL 8 trial (755 women, 30‑33 weeks gestation) found no superiority of atosiban over placebo for a composite of perinatal mortality and severe neonatal morbidity, and maternal adverse events were similar between groups. Earlier maintenance‑tocolysis research reported that a small trial showed atosiban could prolong gestation, though fetal outcomes were not improved. A 2023 meta‑analysis of repeated embryo implantation failure (RIF) patients undergoing IVF‑ET reported a higher clinical pregnancy rate with atosiban (RR 1.54). A 2022 comprehensive review of embryo‑transfer adjuncts identified atosiban among interventions associated with increased clinical pregnancy (RR 1.49), though the evidence was limited to a modest number of RCTs with moderate quality. Reviews also note atosiban as a newer acute tocolytic option compared with beta‑agonists.

Reported Benefits

Evidence suggests atosiban can temporarily halt uterine contractions without raising maternal adverse events, making it a viable acute tocolytic. Small‑scale maintenance studies indicate it may prolong gestation when used beyond the initial 48‑hour window. Meta‑analyses in assisted reproduction show a consistent increase in clinical pregnancy rates for women with repeated implantation failure or undergoing embryo transfer when atosiban is administered around the procedure.

Limitations of the Evidence

The most robust trial (APOSTEL 8) did not demonstrate improved neonatal outcomes, questioning its benefit for routine preterm‑birth management. Maintenance‑tocolysis data rely on a single small trial, limiting confidence. Reproductive‑medicine meta‑analyses include few studies, exhibit heterogeneity, and are of moderate methodological quality, so larger, well‑designed trials are needed before routine adoption. Overall, the clinical impact of atosiban beyond short‑term uterine relaxation remains uncertain.

Safety Considerations

In the APOSTEL 8 trial, maternal adverse events were comparable between atosiban and placebo, and no maternal deaths occurred. No specific serious side‑effects were reported in the reproductive‑medicine studies. As a peptide administered intravenously, standard infusion‑related risks (e.g., phlebitis, hypersensitivity) apply, but current data do not highlight major safety concerns. Caution is advised in patients with known hypersensitivity to peptide drugs.

How It Is Administered

Atosiban is supplied for intravenous infusion, typically initiated as a bolus followed by a maintenance infusion over several hours. It is a prescription‑only medication used in hospital obstetric or fertility units. Formulations are sterile solutions intended for controlled infusion; no oral or other routes are described in the literature.

Routes of Administration

Goals & Uses

• Dysmenorrhea treatmentGynecologyLow
• TocolysisObstetricsModerate
• Tocolysis (preterm labor inhibition)ObstetricsHigh
• Endometrial receptivity improvement (IVF)Reproductive MedicineLow
• Reduction of uterine contractionsObstetricsHigh

Contraindications

• Hypersensitivity to atosiban or excipientsAllergicHigh
• Intrauterine infection (chorioamnionitis)InfectiousHigh
• Gestational age < 24 weeks or > 33+6 weeksObstetricHigh
• Severe hepatic impairmentOrganModerateLiver function concerns
• Placenta praevia with hemorrhageObstetricHigh
• Severe cardiovascular diseaseCardiovascularHigh
• Severe preeclampsia or eclampsiaObstetricHigh
• Intrauterine fetal death or lethal fetal anomalyFetalHigh

Adverse Effects

• HyperglycemiaMetabolicUncommonAbnormally high blood glucose
• Injection site reactionsLocalCommon
• Tachycardia (maternal)CardiovascularUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularRareLow blood pressure
• FlushingVascularUncommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit

Drug Interactions

• OxytocinHigh
• Other tocolytics (e.g., nifedipine)Moderate
• Betamimetics (e.g., ritodrine, terbutaline)Moderate

Population Constraints

• Multiple gestationObstetricRelative
• Hepatic impairment (severe)HepaticRelative
• Renal impairmentOrgan ImpairmentRelative
• Gestational age < 24 weeksObstetricAbsolute
• Gestational age >34 weeksObstetricRelative
• Multiple gestation pregnanciesObstetricRelative

Regulatory Status

• European UnionApprovedApproved: Preterm labor (tocolysis)Marketed as Tractocile.
• United StatesUnapprovedNot submitted for FDA approval.
• United KingdomApprovedApproved: Tocolysis for preterm labor between 24 and 33 weeks gestationApproved and available post-Brexit under MHRA; consistent with prior EU approval

Approved for tocolysis in the European Union and several other countries; not approved by the US FDA.

Evidence & Sources

• Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial
  Journal ArticleModeratevan der Windt LI, et al.2025-01-01T00:00:00.000000Z
• Maintenance tocolysis
  Journal ArticleHighThornton JG2005-01-01T00:00:00.000000Z
• Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis
  Journal ArticleHighWang R, et al.2023-01-01T00:00:00.000000Z
• Acute tocolysis
  Journal ArticleModerateChandraharan E, Arulkumaran S2005-01-01T00:00:00.000000Z
• Interventions to optimize embryo transfer in women undergoing assisted conception: a comprehensive systematic review and meta-analyses
  Journal ArticleHighTyler B, et al.2022-01-01T00:00:00.000000Z

Frequently Asked Questions